Certis

Certis Oncology Solutions is a precision oncology and translational science company that provides advanced functional testing to inform individualized cancer treatment and accelerate drug development. The company is best known for its expertise in orthotopic patient-derived xenograft (O-PDX) models, which more accurately recapitulate the human tumor microenvironment compared to traditional subcutaneous models. By combining these sophisticated in vivo models with CertisAI, a proprietary predictive medicine platform, Certis helps pharmaceutical partners identify the most promising drug candidates and assists oncologists in selecting the most effective therapies for their patients. Their services span from early-stage lead optimization to clinical trial enrichment strategies, utilizing a CLIA-certified and CAP-accredited laboratory.